Senticell

Current plasma-based liquid biopsy diagnostics are severely signal-constrained in early and low-burden disease states, requiring complex analytics to compensate for extremely low circulating tumor DNA. This leads to delayed diagnoses, missed treatment windows, and avoidable clinical and economic harm across oncology, infectious disease, and other conditions.

Senticell's Signal Reservoir Platform enables more sensitive, earlier detection of cancer driver mutations, MRD, and pathogens. The platform is PCR-compatible, low-cost, and designed for sequenced expansion across oncology, infectious disease, and beyond.

Seed round of $6-7M closed; clinical studies underway at UPenn with HPV-driven cancer cohort 60% enrolled and lung cancer cohort 30% enrolled. Technology is backed by 15+ years of peer-reviewed research published in Science Translational Medicine, JCI, and other top journals. Series A of $20M is currently open to fund CLIA build-out, LDT launch, and biopharma RUO partnerships.